scholarly journals The Potential Clinical Benefit of Tocilizumab Therapy for Patients with HHV-8-infected AIDS-related Multicentric Castleman Disease: A Case Report and Literature Review

Cureus ◽  
2020 ◽  
Author(s):  
Gauri Barlingay ◽  
Dawood Findakly ◽  
Carlos Hartmann ◽  
Surabhi Amar
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Clinical Benefit ◽  
Castleman Disease ◽  
Multicentric Castleman Disease ◽  
Potential Clinical Benefit

scholarly journals Unicentric or Multicentric Castleman disease? A case report of a pelvic intraperitoneal mass in a middle aged woman

2019 ◽  
Vol 13 (3) ◽  
Author(s):  
Antonella Smedile ◽  
Francesca Capuano ◽  
Sara Fraticelli ◽  
Marco Lucioni ◽  
Alfredo La Fianza
Keyword(s):  
Case Report ◽  
Castleman Disease ◽  
Middle Aged ◽  
Multicentric Castleman Disease ◽  
Aged Woman ◽  
Middle Aged Woman

Multicentric Castleman disease mimicking IgG4-related disease: A case report

2014 ◽  
Vol 27 (1) ◽  
pp. 174-177 ◽  
Author(s):  
Yasumori Izumi ◽  
Hayato Takeshita ◽  
Yuji Moriwaki ◽  
Keiko Hisatomi ◽  
Masakazu Matsuda ◽  
...  
Keyword(s):  
Case Report ◽  
Castleman Disease ◽  
Multicentric Castleman Disease ◽  
Related Disease ◽  
Igg4 Related Disease

scholarly journals Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Shujing Liang ◽  
Jingxian Yang ◽  
Yun Lin ◽  
Tong Li ◽  
Wenrong Zhao ◽  
...  
Keyword(s):  
Case Report ◽  
Survival Rate ◽  
Side Effects ◽  
Literature Review ◽  
Best Practices ◽  
Adverse Events ◽  
Myasthenia Gravis ◽  
Effective Treatment ◽  
Malignant Tumor ◽  
Clinical Benefit

Immunotherapy begins to be widely used due to the increasing exploration and gratifying effects in multiple cancers. Chordoma, as a rare bone malignant tumor, often recurs and metastasizes after undergoing surgery and radiotherapy. Therefore, immunotherapy can be explored as an emerging, potentially effective treatment to improve the survival rate and clinical benefit of patients. However, a variety of immune-related adverse events (irAEs) cannot be avoided completely. And the immunotherapy-induced myocarditis, as a rare but fatal irAE, has been increasingly reported. Understanding the mechanism involved in irAEs can inform best practices for side effects management. Here, we firstly reported a case of immune myocarditis and subsequent myasthenia gravis (MG) following anti-PD-1 treatment for chordoma.

Sign in / Sign up

Export Citation Format

Share Document